Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 38 points (0.2%) at 16,236 as of Thursday, Feb. 27, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,761 issues advancing vs. 1,149 declining with 174 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.2%. Top gainers within the industry include

Jazz Pharmaceuticals

(

JAZZ

), up 2.7%,

Valeant Pharmaceuticals International

(

VRX

), up 1.6%,

Regeneron Pharmaceuticals

(

REGN

), up 1.2%,

Perrigo Company

(

PRGO

), up 1.2% and

Novartis

(

NVS

), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Intercept Pharmaceuticals

(

ICPT

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Intercept Pharmaceuticals is up $22.67 (5.6%) to $428.78 on average volume. Thus far, 319,577 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 813,600 shares. The stock has ranged in price between $401.08-$430.99 after having opened the day at $409.97 as compared to the previous trading day's close of $406.11.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $7.3 billion and is part of the health care sector. Shares are up 455.2% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts who rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

Intercept Pharmaceuticals

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full

Intercept Pharmaceuticals Ratings Report

TheStreet Recommends

now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Amgen

(

AMGN

) is up $1.65 (1.4%) to $123.51 on light volume. Thus far, 852,843 shares of Amgen exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $121.77-$123.90 after having opened the day at $121.99 as compared to the previous trading day's close of $121.86.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $93.9 billion and is part of the health care sector. Shares are up 9.0% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates

Amgen

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Amgen Ratings Report

now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Pfizer

(

PFE

) is up $0.17 (0.5%) to $32.16 on light volume. Thus far, 9.0 million shares of Pfizer exchanged hands as compared to its average daily volume of 26.4 million shares. The stock has ranged in price between $31.83-$32.24 after having opened the day at $31.87 as compared to the previous trading day's close of $31.99.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $206.7 billion and is part of the health care sector. Shares are up 4.4% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Pfizer

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Pfizer Ratings Report

now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null